drugset / Trial / NCT07174830
Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy Chinese subjects at single dose administration of Allisartan Isoproxil Tablets (240 mg ,480 mg or 720 mg）or placebo. The study design allows an assessment of 3 doses with safety monitoring and PK sampling to evaluate the safety, tolerability and PK profile of Allisartan Isoproxil Tablets.
Timeline
- Start
- 2025-09-06
- Primary completion
- 2025-12-31
- Completion
- 2026-02-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Allisartan Isoproxil | Unknown | 240 mg | — |
| Comparator | Allisartan Isoproxil | Unknown | 480 mg | — |
| Comparator | Allisartan Isoproxil | Unknown | 720 mg | — |
Indications
No indication recorded.